These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22045497)

  • 1. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid.
    Vafadar-Isfahani B; Ball G; Coveney C; Lemetre C; Boocock D; Minthon L; Hansson O; Miles AK; Janciauskiene SM; Warden D; Smith AD; Wilcock G; Kalsheker N; Rees R; Matharoo-Ball B; Morgan K
    J Alzheimers Dis; 2012; 28(3):625-36. PubMed ID: 22045497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
    Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
    J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
    J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression.
    Llano DA; Bundela S; Mudar RA; Devanarayan V;
    PLoS One; 2017; 12(8):e0182098. PubMed ID: 28771542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach.
    van Steenoven I; Koel-Simmelink MJA; Vergouw LJM; Tijms BM; Piersma SR; Pham TV; Bridel C; Ferri GL; Cocco C; Noli B; Worley PF; Xiao MF; Xu D; Oeckl P; Otto M; van der Flier WM; de Jong FJ; Jimenez CR; Lemstra AW; Teunissen CE
    Mol Neurodegener; 2020 Jun; 15(1):36. PubMed ID: 32552841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms.
    Fania C; Arosio B; Capitanio D; Torretta E; Gussago C; Ferri E; Mari D; Gelfi C
    PLoS One; 2017; 12(6):e0179280. PubMed ID: 28628634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease.
    Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J
    Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
    Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
    J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review.
    Wesenhagen KEJ; Teunissen CE; Visser PJ; Tijms BM
    Crit Rev Clin Lab Sci; 2020 Mar; 57(2):86-98. PubMed ID: 31694431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease.
    Öhrfelt A; Brinkmalm A; Dumurgier J; Brinkmalm G; Hansson O; Zetterberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
    Alzheimers Res Ther; 2016 Oct; 8(1):41. PubMed ID: 27716408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
    J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation.
    Wojdała AL; Chiasserini D; Bellomo G; Paciotti S; Gaetani L; Paoletti FP; Parnetti L
    J Alzheimers Dis; 2022; 88(4):1459-1468. PubMed ID: 35786656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease.
    Kitamura Y; Usami R; Ichihara S; Kida H; Satoh M; Tomimoto H; Murata M; Oikawa S
    Neurol Res; 2017 Mar; 39(3):231-238. PubMed ID: 28107809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of 17β-Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias.
    Kristofikova Z; Ricny J; Vyhnalek M; Hort J; Laczo J; Sirova J; Klaschka J; Ripova D
    J Alzheimers Dis; 2015; 48(1):105-14. PubMed ID: 26401932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.
    Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP
    J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update.
    Portelius E; Brinkmalm G; Pannee J; Zetterberg H; Blennow K; Dahlén R; Brinkmalm A; Gobom J
    Expert Rev Proteomics; 2017 Nov; 14(11):1007-1020. PubMed ID: 28942688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease.
    Counts SE; He B; Prout JG; Michalski B; Farotti L; Fahnestock M; Mufson EJ
    Curr Alzheimer Res; 2016; 13(7):800-8. PubMed ID: 26825093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.